Drug news
Abilify Depot(Otsuka/Lundbeck) is filed at FDA for Schizophrenia
The FDA has accepted the application from Otsuka Pharma for Abilify Depot,the once a month version of aripiprazole and Otsuka plans a filing in the EU in 2013. The Abilify patent in the USA will expire in April 2013. Otsuka and Lundbeck have a world wide collaboration to co-develop and co-promote new psychiatric drugs, including Abilify Depot. The companies will co-market in North America, Latin America, Europe and Australia and Otsuka will retain rights in Japan,Asia,Turkey and Egypt. The collaboration extends to OPC 34712 ,an Otsuka drug for schizophrenia and adjunct treatment of major depressive disorder and certain Lundbeck drugs when they complete Phase IIb status.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins